{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:34:55Z","timestamp":1791153295713,"version":"4.1.0"},"reference-count":52,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Intranasal (i.n.) vaccination is potentially the most direct method for conveying upper respiratory and mucosal immunity to respiratory pathogens. However, for unclear reasons, vaccines introduced into the nasal sinuses often have lower efficacy than vaccines administered by the more frequently used parenteral routes. We examined i.n. vaccination in a mouse immune-response model with a commonly used\n            <jats:named-content content-type=\"genus-species\">Haemophilus influenzae<\/jats:named-content>\n            type B vaccine (Hibv) composed of the polyribosylribitol phosphate (PRP) capsule antigen conjugated to tetanus toxoid. Intranasal vaccination with Hibv using a Toll-like receptor 4 (TLR4) agonist as an adjuvant significantly increased the levels of IgA specific for the PRP capsule antigen in blood serum, saliva, and mucosal secretion specimens. In contrast, control mice vaccinated transdermally (t.d.) with Hibv did not produce significant levels of PRP-specific IgA in the blood serum and saliva, and anti-PRP IgG was increased only in serum. The i.n. and t.d. vaccinations resulted in equivalent bactericidal antibody responses in blood serum, suggesting that vaccine-derived IgG is protective against infection. Elevated levels of IgG specific for the tetanus toxoid carrier protein were measured in nasal sinuses and vaginal secretions in mice vaccinated by either the t.d. or i.n. route. Tissue culture studies confirmed that the nasopharynx-associated lymphoid tissue (NALT) was at least one of the sources of PRP-specific IgA and carrier-specific IgG within the nasal sinuses. We conclude that i.n. vaccination aided by a TLR4 agonist results in robust immune responses to both the carrier protein and bacterial polysaccharide components of the Hibv.\n          <\/jats:p>","DOI":"10.1128\/cvi.00215-13","type":"journal-article","created":{"date-parts":[[2013,8,29]],"date-time":"2013-08-29T03:42:52Z","timestamp":1377747772000},"page":"1690-1696","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["Enhancement of Serum and Mucosal Immune Responses to a Haemophilus influenzae Type B Vaccine by Intranasal Delivery"],"prefix":"10.1128","volume":"20","author":[{"given":"Stefan","family":"Fernandez","sequence":"first","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily D.","family":"Cisney","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Ulrich","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1086\/586716","article-title":"School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom","volume":"197","author":"Oh SY","year":"2008","unstructured":"OhSYGriffithsDJohnTLeeYCYuLMMcCarthyNHeathPTCrookDRamsayMMoxonERPollardAJ. 2008. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J. Infect. Dis. 197:1275\u20131281.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02200-10"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1086\/315870","article-title":"Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration","volume":"182","author":"Fernandez J","year":"2000","unstructured":"FernandezJLevineOSSanchezJBalterSLaClaireLFerisJRomero-SteinerS. 2000. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J. Infect. Dis. 182:1553\u20131556.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(09)61203-4","article-title":"Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates","volume":"374","author":"Watt JP","year":"2009","unstructured":"WattJPWolfsonLJO'BrienKLHenkleEDeloria-KnollMMcCallNLeeELevineOSHajjehRMulhollandKCherianTHib and Pneumococcal Global Burden of Disease Study Team. 2009. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 374:903\u2013911.","journal-title":"Lancet"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0264-410X(94)00042-L","article-title":"Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines","volume":"13","author":"Siber GR","year":"1995","unstructured":"SiberGRAndersonRHabafyMGuptaRK. 1995. Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines. Vaccine 13:525\u2013531.","journal-title":"Vaccine"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165-Supplement_1-S49"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1006\/biol.1994.1052","article-title":"Combination of DTP and Haemophilus influenzae type b conjugate vaccines can affect laboratory evaluation of potency and immunogenicity","volume":"22","author":"Redhead K","year":"1994","unstructured":"RedheadKSesardicDYostSEAttwellAMWatkinsJHoyCSPlumbJECorbelMJ. 1994. Combination of DTP and Haemophilus influenzae type b conjugate vaccines can affect laboratory evaluation of potency and immunogenicity. Biologicals 22:339\u2013345.","journal-title":"Biologicals"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1128\/IAI.67.12.6375-6384.1999","article-title":"Cognate stimulatory B-cell\u2013T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines","volume":"67","author":"Guttormsen HK","year":"1999","unstructured":"GuttormsenHKSharpeAHChandrakerAKBrigtsenAKSayeghMHKasperDL. 1999. Cognate stimulatory B-cell\u2013T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect. Immun. 67:6375\u20136384.","journal-title":"Infect. Immun."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/nm.2587","article-title":"A sweet T cell response","volume":"17","author":"Rappuoli R","year":"2011","unstructured":"RappuoliRDe GregorioE. 2011. A sweet T cell response. Nat. Med. 17:1551\u20131552.","journal-title":"Nat. Med."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/nm.2535","article-title":"A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design","volume":"17","author":"Avci FY","year":"2011","unstructured":"AvciFYLiXTsujiMKasperDL. 2011. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat. Med. 17:1602\u20131609.","journal-title":"Nat. Med."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1016\/S0264-410X(01)00048-2","article-title":"The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines","volume":"19","author":"von Hunolstein C","year":"2001","unstructured":"von HunolsteinCMariottiSTeloniRAlfaroneGRomagnoliGOreficiGNisiniR. 2001. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine 19:3058\u20133066.","journal-title":"Vaccine"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2249.1998.00501.x","article-title":"Subclass distribution of IgA antibodies in saliva and serum after immunization with Haemophilus influenzae type b conjugate vaccines","volume":"111","author":"Kauppi-Korkeila M","year":"1998","unstructured":"Kauppi-KorkeilaMSaarinenLEskolaJKayhtyH. 1998. Subclass distribution of IgA antibodies in saliva and serum after immunization with Haemophilus influenzae type b conjugate vaccines. Clin. Exp. Immunol. 111:237\u2013242.","journal-title":"Clin. Exp. Immunol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00477-10"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2003.02311.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.5.2532"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.007"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00097-X"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.12.8126"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.4.1796"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.1.625-631.2006"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1128\/IAI.68.10.5749-5755.2000","article-title":"Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine","volume":"68","author":"Shen X","year":"2000","unstructured":"ShenXLagerg\u00e5rdTYangYLindbladMFredrikssonMHolmgrenJ. 2000. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine. Infect. Immun. 68:5749\u20135755.","journal-title":"Infect. Immun."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0264-410X(00)00226-7","article-title":"Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization","volume":"19","author":"Shen X","year":"2000","unstructured":"ShenXLagerg\u00e5rdTYang YLindbladFredrikssonMHolmgrenJ. 2000. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization. Vaccine 19:850\u2013861.","journal-title":"Vaccine"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/S0264-410X(02)00113-5","article-title":"Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant","volume":"20","author":"Mariotti S","year":"2002","unstructured":"MariottiSTeloniRvon HunolsteinCRomagnoliGOreficiGNisiniR. 2002. Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant. Vaccine 20:2229\u20132239.","journal-title":"Vaccine"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1086\/344320","article-title":"Combinations of protein polysaccharide conjugate vaccines for intranasal immunization","volume":"186","author":"Ugozzoli M","year":"2002","unstructured":"UgozzoliMMarianiMDel GiudiceGSoenawanEO'HaganDT. 2002. Combinations of protein polysaccharide conjugate vaccines for intranasal immunization. J. Infect. Dis. 186:1358\u20131361.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01564-08"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00153-07"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.4.2031-2036.2001"},{"key":"e_1_3_2_29_2","first-page":"1489","article-title":"Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines","volume":"267","author":"Schlesinger Y","year":"1992","unstructured":"SchlesingerYGranoffDM. 1992. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 267:1489\u20131494.","journal-title":"The Vaccine Study Group. JAMA"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.8.6.1115-1119.2001"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/infdis\/167.2.365","article-title":"Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats","volume":"167","author":"Kauppi M","year":"1993","unstructured":"KauppiMSaarinenLK\u00e4yhtyH. 1993. Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats. J. Infect. Dis. 167:365\u2013371.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00006454-199504000-00008","article-title":"Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines","volume":"14","author":"Kauppi M","year":"1995","unstructured":"KauppiMEskolaJK\u00e4yhtyH. 1995. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr. Infect. Dis. J. 14:286\u2013294.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/infdis\/174.6.1337","article-title":"Mechanism of antibody-mediated reduction of nasopharyngeal colonization by Haemophilus influenzae type b studied in an infant rat model","volume":"174","author":"Kauppi-Korkeila M","year":"1996","unstructured":"Kauppi-KorkeilaMvan AlphenLMadoreDSaarinenLK\u00e4yhtyH. 1996. Mechanism of antibody-mediated reduction of nasopharyngeal colonization by Haemophilus influenzae type b studied in an infant rat model. J. Infect. Dis. 174:1337\u20131340.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1086\/338259","article-title":"Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed","volume":"34","author":"Breukels MA","year":"2002","unstructured":"BreukelsMAJol-van der ZijdeEvan TolMJRijkersGT. 2002. Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed. Clin. Infect. Dis. 34:191\u2013197.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1086\/524668","article-title":"Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody","volume":"46","author":"Lee YC","year":"2008","unstructured":"LeeYCKellyDFYuLMSlackMPBooyRHeathPTSiegristCAMoxonREPollardAJ. 2008. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin. Infect. Dis. 46:186\u2013192.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1749-6632.2011.06356.x","article-title":"Sulfated glycans control lymphocyte homing","volume":"1253","author":"Kawashima H","year":"2012","unstructured":"KawashimaHFukudaM. 2012. Sulfated glycans control lymphocyte homing. Ann. N. Y. Acad. Sci. 1253:112\u2013121.","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(99)01468-1"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0167-5699(98)01413-3","article-title":"Regional specialization in the mucosal immune system: what happens in the microcompartments?","volume":"20","author":"Brandtzaeg P","year":"1999","unstructured":"BrandtzaegPBaekkevoldESFarstadINJahnsenFLJohansenFENilsenEMYamanakaT. 1999. Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol. Today 20:141\u2013151.","journal-title":"Immunol. Today"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1203"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025396"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.vetimm.2009.08.011","article-title":"NALT (nasal cavity-associated lymphoid tissue) in the rabbit","volume":"133","author":"Casteleyn C","year":"2009","unstructured":"CasteleynCBroosAMSimoensPVan den BroeckW. 2009. NALT (nasal cavity-associated lymphoid tissue) in the rabbit. Vet. Immunol. Immunopathol. 133:212\u2013218.","journal-title":"Vet. Immunol. Immunopathol."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(96)00243-8"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.7.4276"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.8.4904"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.3.986"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1439"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200211)32:11<3191::AID-IMMU3191>3.0.CO;2-0"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00299.x"},{"issue":"4","key":"e_1_3_2_49_2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1164\/ajrccm.156.4.97-03017","article-title":"Comparison of murine nasal-associated lymphoid tissue and Peyer's patches","volume":"156","author":"Heritage PL","year":"1997","unstructured":"HeritagePLUnderdownBJArsenaultALSnidenDPMcDermottMR. 1997. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Am. J. Respir. Crit. Care Med. 156(4 Pt 1):1256\u20131262.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-12-7"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.06.091"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1586\/erv.09.80","article-title":"Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines","volume":"8","author":"Kataoka K","year":"2009","unstructured":"KataokaKFujihashiK. 2009. Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines. Expert Rev. Vaccines 8:1183\u20131193.","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/S0264-410X(02)00247-5","article-title":"Tracking the tissue distribution of marker dye following intranasal delivery in mice and chinchillas: a multifactorial analysis of parameters affecting nasal retention","volume":"20","author":"Visweswaraiah A","year":"2002","unstructured":"VisweswaraiahANovotnyLAHjemdahl-MonsenEJBakaletzLOThanavalaY. 2002. Tracking the tissue distribution of marker dye following intranasal delivery in mice and chinchillas: a multifactorial analysis of parameters affecting nasal retention. Vaccine 20:3209\u20133220.","journal-title":"Vaccine"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00215-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00215-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:48:07Z","timestamp":1627591687000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00215-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1128\/CVI.00215-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00215-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"2013-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}